Nitromed (NTMD) Question

Nitromed received the first ever ethnic/race specific drug approval for a drug for cardiac disease -- for African Americans. The company has been unable to sell it in voilume due to pricing and reimbursement issues and I believe continuning skepticism about this kind of drug, depsite trial results that showed a greater than 40% redcution in deaths. At this time, the company does not have the resources or management talent to "break out" -- get the drug moving int he markelpace -- and I would avoid th stock until there is evidence they can fix this sales problem. Admittedly, if they solve the problem with a powerful partnership, the stock will probabyl run away before it can be bought but it is a tock worth missing until there is hard news.